(603087)"Gan & Lee Pharmaceuticals"Announcement on Convening the Q3 2026 Performance Briefing
Filed with SSE · Stock code 603087 · · 2 pages · Chinese
Summary by 6ix AI
It will be held at the Shanghai Stock Exchange's online interaction platform, allowing investors to participate and ask questions. The company aims to discuss its operational performance and strategy during this session.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Gan & Lee Pharmaceuticals Co., Ltd. on 6ix
Story so far
- (603087)"Gan & Lee Pharmaceuticals"Announcement on Obtaining Notice of Approval for Drug Clinical Trials
- (603087)"Gan & Lee Pharmaceuticals"Announcement on Acquisition of Pharmaceutical Registration Approval for Insulin Glargine Injection (Cartridge) in El Salvador
- (603087)"Gan & Lee Pharmaceuticals"Announcement on Acquisition of Pharmaceutical Registration Approval for Insulin Glargine Injection (Pre-filled Pen) in El Salvador
Earlier from Gan & Lee Pharmaceuticals
- (603087)"Gan & Lee Pharmaceuticals"Report for Q3 2026
- (603087)"Gan & Lee Pharmaceuticals"Announcement on Obtaining Notice of Approval for Drug Clinical Trials
- (603087)"Gan & Lee Pharmaceuticals"Announcement on Acquisition of Pharmaceutical Registration Approval for Insulin Glargine Injection (Cartridge) in El Salvador
- (603087)"Gan & Lee Pharmaceuticals"Announcement on Completion of First Subject Dosing in the Phase I Clinical Trial of GLR1075 Injection
- (603087)"Gan & Lee Pharmaceuticals"Announcement on Acquisition of Pharmaceutical Registration Approval for Insulin Glargine Injection (Pre-filled Pen) in El Salvador
Later from Gan & Lee Pharmaceuticals
All Gan & Lee Pharmaceuticals news releasesFollow Gan & Lee Pharmaceuticals into a list and get an email when it puts out news.
Follow Gan & Lee Pharmaceuticals